Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

1.4%

4 terminated/withdrawn out of 280 trials

Success Rate

92.3%

+5.8% vs industry average

Late-Stage Pipeline

18%

49 trials in Phase 3/4

Results Transparency

2%

1 of 48 completed trials have results

Key Signals

57 recruiting1 with results

Enrollment Performance

Analytics

N/A
91(43.8%)
Phase 4
35(16.8%)
Phase 2
29(13.9%)
Early Phase 1
20(9.6%)
Phase 1
19(9.1%)
Phase 3
14(6.7%)
208Total
N/A(91)
Phase 4(35)
Phase 2(29)
Early Phase 1(20)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (280)

Showing 20 of 280 trials
NCT07469046Phase 3Not Yet Recruiting

VAH vs VA in Newly Diagnosed Elderly AML

Role: lead

NCT07522164Active Not Recruiting

Acute Myocardial Infarction Clinical Cohort

Role: collaborator

NCT06832774Phase 2Recruiting

Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients

Role: lead

NCT07488299Not ApplicableNot Yet Recruiting

The Effect of PPI on Endoscopic Treatment of WON: a Multicenter Randomized Controlled Trial.

Role: collaborator

NCT07353398Early Phase 1Not Yet Recruiting

Early-phase Study of ART002g1 Injection in HeFH: Safety, Tolerability and Preliminary Efficacy

Role: lead

NCT06839170Not ApplicableCompleted

An Assistant Model for IRD Care Needs: A Randomized Control Trial

Role: lead

NCT07470996Recruiting

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR

Role: lead

NCT07463313Phase 2Not Yet Recruiting

6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors

Role: lead

NCT07053358Early Phase 1Recruiting

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

Role: lead

NCT07362927Early Phase 1Recruiting

Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients

Role: lead

NCT07063030Early Phase 1Recruiting

A Study of LX107 Gene Therapy in AIPL1-IRD Patients

Role: lead

NCT07083154Phase 3Recruiting

GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)

Role: collaborator

NCT06483906Phase 2Recruiting

Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.

Role: lead

NCT07439120Early Phase 1Not Yet Recruiting

Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors

Role: lead

NCT07434518Recruiting

A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC

Role: lead

NCT07291089Phase 4Completed

Iris Vascular Area Density-Based Preoperative Pain-Risk Screening and Intervention in Second-Eye Cataract Surgery

Role: lead

NCT07371520Not Yet Recruiting

Application of Quantitative Hemorrhage Detection in Fetomaternal Hemorrhage Syndrome for the Diagnosis of Hemolytic Disease of the Newborn

Role: lead

NCT07414758Phase 3Recruiting

Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy

Role: lead

NCT07414277Not ApplicableNot Yet Recruiting

CGM for Insulin-Treated T2DM During Post-Discharge Transition

Role: collaborator

NCT05888350Not ApplicableCompleted

Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough.

Role: collaborator